银屑病患者起始生物制剂治疗发生炎症性关节炎的风险:人群分析
基于Optum数据库2007年1月至2023年3月无基线炎症性关节炎诊断的银屑病患者,按初始生物制剂类别分层随访至多3年。IL-23、IL-17、IL-12/23和TNF抑制剂的发生率分别为4.99、7.29、6.06和9.39事件/100人年;以IL-23为参照,IL-17和TNF抑制剂调整后风险显著更高。
要点
- 以IL-23抑制剂为参照,IL-17抑制剂发生炎症性关节炎风险显著更高(aHR 1.44)。
- TNF抑制剂发生炎症性关节炎风险显著更高(aHR 1.90)。
- IL-23抑制剂治疗者炎症性关节炎发生率最低(4.99事件/100人年)。
核心结论
- 接受IL-23抑制剂的患者发生炎症性关节炎或银屑病关节炎的风险低于接受IL-17和TNF抑制剂的患者。
研究设计与样本
- 回顾性研究,使用Optum Clinformatics Data Mart数据库2007年1月至2023年3月无基线炎症性关节炎诊断的银屑病患者。
- 按初始生物制剂类别(IL-23、IL-12/23、IL-17或TNF抑制剂)分层,随访至多3年或发生炎症性关节炎。
- 采用多变量Cox比例风险模型,以IL-23抑制剂为参照评估发生炎症性关节炎的风险。
主要发现
- 发生炎症性关节炎的发生率(事件/100人年)分别为:IL-23抑制剂4.99、IL-17抑制剂7.29、IL-12/23抑制剂6.06、TNF抑制剂9.39。
- 与IL-23抑制剂相比,IL-17抑制剂的调整后风险比显著更高(1.44;P = .0294)。
- 与IL-23抑制剂相比,TNF抑制剂的调整后风险比显著更高(1.90;P < .0001)。
临床怎么用
- 对于银屑病患者选择初始生物制剂时,可考虑IL-23抑制剂与较低的炎症性关节炎发生风险相关。
局限性
- 局限性包括医疗编码错误相关的问题以及潜在的原偏倚(protopathic bias)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between biologic treatments for psoriasis (PsO) and the development of inflammatory arthritis in patients is not fully understood. OBJECTIVE: The objective of this study was to analyze the effects of biologic treatment on the development of inflammatory arthritis in patients with PsO. METHODS: This retrospective study assessed patients with PsO identified in the Optum Clinformatics Data Mart database from Jan 2007 to Mar 2023 with no baseline diagnosis of inflammatory arthritis. Patients were stratified based on the class of initial biologic treatment (interleukin [IL] 23, IL-12/23, IL-17, or tumor necrosis factor [TNF] inhibitor) and followed for up to 3 years or development of inflammatory arthritis. Risk of developing inflammatory arthritis was assessed using a multivariate Cox proportional hazard model using IL-23 inhibitors as reference. RESULTS: Incidence rates of developing inflammatory arthritis expressed as events/100 person-years were 4.99, 7.29, 6.06, and 9.39 for IL-23, IL-17, IL-12/23, and TNF inhibitors, respectively. Adjusted hazard ratios were significantly higher for patients receiving IL-17 (1.44; P = .0294) and TNF (1.90; P < .0001) inhibitors when compared with patients receiving IL-23 inhibitors. LIMITATIONS: Limitations include those associated with medical coding errors and the potential for protopathic bias. CONCLUSION: Patients receiving IL-23 inhibitors are at lower risk of developing inflammatory arthritis or psoriatic arthritis than those receiving IL-17 and TNF inhibitors.
引用
- Strober B, Soliman AM, Li C, et al. Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: A population-based analysis. J Am Acad Dermatol. 2024. PMID: 39197499. doi:10.1016/j.jaad.2024.06.106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。